Nicergoline Tablets

Category B under National Medical Insurance

[Drug Name]

Generic name: Nimaijiaolin tablets

[Indications]

1. Improvement of reduced initiative (apathy) caused by sequelae of cerebral infarction.

2. Also indicated for vascular dementia, especially in early treatment, with benefits for cognition and memory, and reducing disease severity.

[Dosage and Administration]

Oral administration, do not chew. Usual dose: 20–60 mg daily, divided into 2–3 doses. Continuous administration for a sufficient period, at least 6 months; continuation to be determined by physician.

• Patients with renal impairment:

As renal excretion is the main elimination route for nicergoline and its metabolites (80%), dosage should be reduced in patients with renal impairment. Physicians should assess at appropriate intervals (at least once every 6 months) whether to continue treatment.

[ Contraindications ]

Not suitable for patients with recent myocardial infarction, acute bleeding, severe bradycardia, orthostatic hypotension, bleeding tendency, or hypersensitivity to the active substance, ergot alkaloids, or any excipients.

[Specification]

30 mg

[Shelf Life]

24 months

[Approval Number]

National Medical Products Administration Approval Number: H20234574

Hotline: 0591-83512959

Back